Terms: = Bone cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
108 results:
1. Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies.
Shen X; Dong P; Kong J; Sun N; Wang F; Sang L; Xu Y; Zhang M; Chen X; Guo R; Wang S; Lin Q; Jiang Z; Xu S; Zhang C; Bian Z; Wang W; Guo R
Cell Biochem Funct; 2023 Dec; 41(8):1343-1356. PubMed ID: 37823726
[TBL] [Abstract] [Full Text] [Related]
2. Comparative bioinformatic analysis of kras, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on kras G12C.
Boeschen M; Kuhn CK; Wirtz H; Seyfarth HJ; Frille A; Lordick F; Hacker UT; Obeck U; Stiller M; Bläker H; von Laffert M
Lung Cancer; 2023 Oct; 184():107361. PubMed ID: 37699269
[TBL] [Abstract] [Full Text] [Related]
3. Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung cancer Patients.
Leest PV; Janning M; Rifaela N; Azpurua MLA; Kropidlowski J; Loges S; Lozano N; Sartori A; Irwin D; Lamy PJ; Hiltermann TJN; Groen HJM; Pantel K; Kempen LCV; Wikman H; Schuuring E
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686200
[TBL] [Abstract] [Full Text] [Related]
4. RAS‑stimulated release of exosomal
Kim O; Tran PT; Gal M; Lee SJ; Na SH; Hwangbo C; Lee JH
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37503759
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study.
Ma K; Guo Q; Li X
BMC Pulm Med; 2023 May; 23(1):175. PubMed ID: 37208639
[TBL] [Abstract] [Full Text] [Related]
6. Molecular markers of metastatic disease in kras-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract] [Full Text] [Related]
7. A spotlight on the interplay of signaling pathways and the role of miRNAs in osteosarcoma pathogenesis and therapeutic resistance.
Doghish AS; Hegazy M; Ismail A; El-Mahdy HA; Elsakka EGE; Elkhawaga SY; Elkady MA; Yehia AM; Abdelmaksoud NM; Mokhtar MM
Pathol Res Pract; 2023 May; 245():154442. PubMed ID: 37031532
[TBL] [Abstract] [Full Text] [Related]
8. Adverse reactions and efficacy of camrelizumab in patients with lung adenocarcinoma with high PD-L1 expression: A case report.
Wei T; Wang Z; Liu X
Medicine (Baltimore); 2023 Feb; 102(7):e32731. PubMed ID: 36800626
[TBL] [Abstract] [Full Text] [Related]
9. Genomic features and its potential implication in bone oligometastatic NSCLC.
Liao R; Yi G; Shen L; Zhang X; Xu Z; Peng Y; Yang Z
BMC Pulm Med; 2023 Feb; 23(1):59. PubMed ID: 36755257
[TBL] [Abstract] [Full Text] [Related]
10. Targeting SOST using a small-molecule compound retards breast cancer bone metastasis.
Sun L; Zhang Y; Chen G; Ji Y; Ma Q; Qiao X; Wu S; Zhou L; Bu J; Zhu X; Zhang X; Jiang X; Liu C; Li X; Liu Y; Yang Y; Liu C
Mol Cancer; 2022 Dec; 21(1):228. PubMed ID: 36581888
[TBL] [Abstract] [Full Text] [Related]
11. Deep learning-based assessment of body composition and liver tumour burden for survival modelling in advanced colorectal cancer.
Keyl J; Hosch R; Berger A; Ester O; Greiner T; Bogner S; Treckmann J; Ting S; Schumacher B; Albers D; Markus P; Wiesweg M; Forsting M; Nensa F; Schuler M; Kasper S; Kleesiek J
J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):545-552. PubMed ID: 36544260
[TBL] [Abstract] [Full Text] [Related]
12. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
Stahl M; Derkach A; Farnoud N; Bewersdorf JP; Robinson T; Famulare C; Cho C; Devlin S; Menghrajani K; Patel MA; Cai SF; Miles LA; Bowman RL; Geyer MB; Dunbar A; Epstein-Peterson ZD; McGovern E; Schulman J; Glass JL; Taylor J; Viny AD; Stein EM; Getta B; Arcila ME; Gao Q; Barker J; Shaffer BC; Papadopoulos EB; Gyurkocza B; Perales MA; Abdel-Wahab O; Levine RL; Giralt SA; Zhang Y; Xiao W; Pai N; Papaemmanuil E; Tallman MS; Roshal M; Goldberg AD
Am J Hematol; 2023 Jan; 98(1):79-89. PubMed ID: 36251406
[TBL] [Abstract] [Full Text] [Related]
13. MSC-Derived exosomes suppress colorectal cancer cell proliferation and metastasis via miR-100/mTOR/miR-143 pathway.
Jahangiri B; Khalaj-Kondori M; Asadollahi E; Purrafee Dizaj L; Sadeghizadeh M
Int J Pharm; 2022 Nov; 627():122214. PubMed ID: 36152993
[TBL] [Abstract] [Full Text] [Related]
14. Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review.
Masuda T; Kosaka T; Nakamura K; Hongo H; Yuge K; Nishihara H; Oya M
BMC Med Genomics; 2022 May; 15(1):118. PubMed ID: 35598018
[TBL] [Abstract] [Full Text] [Related]
15. The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.
Song J; Zhang H; Dong N; Zhang X; Hussaini M; Jain A; Moscinski L; Shain K; Baz R; Alsina M; Nishihori T; Zhang L
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e414-e426. PubMed ID: 34998786
[TBL] [Abstract] [Full Text] [Related]
16. Case report: Rare myeloid sarcoma development following renal transplantation with kras and DNMT3A gene mutations.
Wu D; Lu X; Yan X; Gao R
Diagn Pathol; 2021 Aug; 16(1):82. PubMed ID: 34465355
[TBL] [Abstract] [Full Text] [Related]
17. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
Park HS; Son BR; Shin KS; Byeon S; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
Acta Haematol; 2021; 144(6):649-659. PubMed ID: 34233332
[TBL] [Abstract] [Full Text] [Related]
18. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.
Arriaga JM; Panja S; Alshalalfa M; Zhao J; Zou M; Giacobbe A; Madubata CJ; Kim JY; Rodriguez A; Coleman I; Virk RK; Hibshoosh H; Ertunc O; Ozbek B; Fountain J; Jeffrey Karnes R; Luo J; Antonarakis ES; Nelson PS; Feng FY; Rubin MA; De Marzo AM; Rabadan R; Sims PA; Mitrofanova A; Abate-Shen C
Nat Cancer; 2020 Nov; 1(11):1082-1096. PubMed ID: 34085047
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal cancer.
Yin J; Cohen R; Jin Z; Liu H; Pederson L; Adams R; Grothey A; Maughan TS; Venook A; Van Cutsem E; Punt C; Koopman M; Falcone A; Tebbutt NC; Seymour MT; Bokemeyer C; Rubio ED; Kaplan R; Heinemann V; Chibaudel B; Yoshino T; Zalcberg J; Andre T; De Gramont A; Shi Q; Lenz HJ
J Natl Cancer Inst; 2021 Nov; 113(12):1705-1713. PubMed ID: 34061178
[TBL] [Abstract] [Full Text] [Related]
20. Toxicity of Combinations of Kinase Pathway Inhibitors to Normal Human Cells in a Three-Dimensional Culture.
Rafsanjani Nejad P; Shahi Thakuri P; Singh S; Lamichhane A; Heiss J; Tavana H
SLAS Technol; 2021 Jun; 26(3):255-264. PubMed ID: 33880947
[TBL] [Abstract] [Full Text] [Related]
[Next]
